Mianserin
| Clinical data | |
|---|---|
| Trade names | Tolvon, others |
| Other names | Mianserin hydrochloride; Org GB 94 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 20–30% |
| Protein binding | 95% |
| Metabolism | Liver (CYP2D6; via aromatic hydroxylation, N-oxidation, N-demethylation) |
| Elimination half-life | 21–61 hours |
| Excretion | Urine: 4–7% Feces: 14–28% |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.041.884 |
| Chemical and physical data | |
| Formula | C18H20N2 |
| Molar mass | 264.372 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Mianserin, sold as Tolvon and other brand names, is an atypical antidepressant used primarily for treating depression in Europe and other countries. It is a tetracyclic antidepressant (TeCA) and is closely related to mirtazapine in terms of chemical structure, actions, and effects, although mianserin has greater noradrenergic activity and less 5-HT3 receptor antagonism.